Stock Market News
Optibiotix Health launches first product from Seed collaboration
Life sciences firm Optibiotix Health on Thursday launched a new product in the US that contains its LPLDL cholesterol-reducing and blood pressure-reducing strain.
The product is the first to be launched since Optibiotix and Seed Health entered into a non-exclusive agreement to produce, promote, market and commercialise products containing LPLDL in the US on 22 May.
Stephen O'Hara, chief executive of OptiBiotix, said: "We are excited to see the launch of products containing our cholesterol reducing LPLDL strain in the USA, the world's largest and fastest growing probiotic market. The launch with Seed substantiates the science behind LPLDL and helps build the LPLDL brand in the consumer healthcare market around the world."
The AIM-traded company described LPLDL as an "innovative product concept" which combines multiple strains of various probiotics which have been selected because of strong clinical trial data.
The product will be marketed by Seed under the brandname Daily Synbiotic and is available to customers directly through the company website.
"We hope this will be the first of many product launches of multiple formulations and presentations of LPLDL as the active component in a wide range of products in the USA and around the world," said O'Hara.
As of 0917 BST, Optibiotix Health's shares were unchanged at 70.50p.
The product is the first to be launched since Optibiotix and Seed Health entered into a non-exclusive agreement to produce, promote, market and commercialise products containing LPLDL in the US on 22 May.
Stephen O'Hara, chief executive of OptiBiotix, said: "We are excited to see the launch of products containing our cholesterol reducing LPLDL strain in the USA, the world's largest and fastest growing probiotic market. The launch with Seed substantiates the science behind LPLDL and helps build the LPLDL brand in the consumer healthcare market around the world."
The AIM-traded company described LPLDL as an "innovative product concept" which combines multiple strains of various probiotics which have been selected because of strong clinical trial data.
The product will be marketed by Seed under the brandname Daily Synbiotic and is available to customers directly through the company website.
"We hope this will be the first of many product launches of multiple formulations and presentations of LPLDL as the active component in a wide range of products in the USA and around the world," said O'Hara.
As of 0917 BST, Optibiotix Health's shares were unchanged at 70.50p.
Related share prices |
---|
OptiBiotix Health (OPTI) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price